Fund Holdings — Rosalind Advisors, Inc.

Total Portfolio Value
$244.08M
Total Bought
$76.43M
Total Sold
$90.39M
Net Transaction
-$13.95M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q4 2025
▲▼
Q1 2026
▲▼
Change
▲▼
Q4 2025
▲▼
Q1 2026
▲▼
Weight (%)
▲▼
Change
▲▼
VAXCYTE INC(PCVX)0290,000+290,000016,8526.90%+16,852
VOR BIOPHARMA INC(VOR)0700,000+700,000012,4885.12%+12,488
CELLDEX THERAPEUTICS INC(CLDX)0330,000+330,000010,4684.29%+10,468
BIOCRYST PHARMACEUTICALS INC(BCRX)0923,057+923,05708,7883.60%+8,788
ATEA PHARMACEUTICALS INC(AVIR)01,171,855+1,171,85506,3052.58%+6,305
X4 PHARMACEUTICALS INC(XFOR)2,605,9203,214,766+608,84610,42413,2775.44%+2,853
OVID THERAPEUTICS INC(OVID)01,107,994+1,107,99402,4601.01%+2,460
DEFINIUM THERAPEUTICS INC(DFTX)0125,000+125,00002,3630.97%+2,363
XERIS BIOPHARMA HOLDINGS INC2,111,7003,231,700+1,120,00016,57718,7447.68%+2,167
LIPOCINE INC(LPCN)0221,616+221,61601,7710.73%+1,771
AVALO THERAPEUTICS INC(AVTX)075,000+75,00001,1200.46%+1,120
ANNEXON INC(ANNX)0200,000+200,00001,1080.45%+1,108
AQUESTIVE THERAPEUTICS INC0250,000+250,00001,0380.43%+1,038
EYEPOINT PHARMACEUTICALS INC(EYPT)690,0001,036,737+346,73712,60613,3645.48%+757
NEURAXIS INC(NRXS)286,138286,13801,0391,6940.69%+655
BIOFRONTERA INC(BFRI)1,140,7641,163,962+23,1986509420.39%+291
KURA ONCOLOGY INC(KURA)100,000100,00001,0398130.33%-226
ONKURE THERAPEUTICS INC(OKUR)730,488443,763-286,7252,1181,8370.75%-281
POLYPID LTD(PYPD)696,556597,926-98,6303,0232,6191.07%-404
INSPIREMD INC(NSPR)3,905,7433,905,74306,9526,3662.61%-586
FRACTYL HEALTH INC(GUTS)385,7310-385,7318490—-849
MYOMO INC(MYO)3,839,7723,847,272+7,5003,4942,5991.06%-895
REGENTIS BIOMATERIALS LTD(RGNT)251,510251,51001,6957680.31%-927
TREVI THERAPEUTICS INC(TRVI)100,0000-100,0001,2520—-1,252
TALPHERA INC(TLPH)3,579,2733,353,916-225,3574,0802,5051.03%-1,575
MEDIWOUND LTD(MDWD)749,054749,054013,82812,0674.94%-1,760
FENNEC PHARMACEUTICALS INC(FENC)2,613,5082,908,201+294,69320,12417,8857.33%-2,239
DELCATH SYSTEMS, INC.(DCTH)3,300,3893,300,389033,00430,62812.55%-2,376
VERASTEM INC(VSTM)1,788,4752,138,475+350,00013,80711,3344.64%-2,473
SAVARA INC(SVRA)3,403,7213,203,721-200,00020,52417,4927.17%-3,032
PROFOUND MEDICAL CORP(PROF)1,068,955828,118-240,8378,4135,3662.20%-3,046
ARRIVENT BIOPHARMA INC(AVBP)215,8710-215,8714,3430—-4,343
Ocular Therapeutix, Inc(OCUL)400,0000-400,0004,8560—-4,856
CG ONCOLOGY INC(CGON)300,000100,000-200,00012,4566,7682.77%-5,688
CYBIN INC(HELP)1,657,5401,531,814-125,72613,5597,3533.01%-6,206
VIRIDIAN THERAPEUTICS INC(VRDN)450,000250,401-199,59914,0044,8982.01%-9,106
MIND MEDICINE MINDMED INC750,0000-750,00010,0430—-10,042
CYTOKINETICS INC(CYTK)195,0450-195,04512,3930—-12,393
ASTRIA THERAPEUTICS INC1,039,0800-1,039,08013,6020—-13,602
REPLIMUNE GROUP INC(REPL)1,410,4970-1,410,49713,7100—-13,710
Page 1 of 1
Rosalind Advisors, Inc. — 13F Holdings — Q1 2026 | TickerTrail